Ken Banta and Andrew Hall share insights on leading through uncertainty—covering culture, capital, risk, and the regulatory ...

Yerem Yeghiazarians founder, CEO of Soley Therapeutics, discusses how Soley uses human cells to guide drug discovery, ...

The EY deals leader discusses recent findings and trends from 2025.

Yerem Yeghiazarians founder and CEO of Soley Therapetuics touches on how Soley's approach reverses traditional drug development and reduces failure risks.

In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate ...

Yerem Yeghiazarians founder and CEO of Soley Therapetuics touches on how Soley's approach reverses traditional drug development and reduces failure risks.

Novo Nordisk, the manufacturer of Wegovy, responded strongly to the initial launch of Hims & Hers’ compounded semaglutide ...

Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the ...

Real-world data (RWD) is transforming clinical research, augmenting existing randomized controlled trial (RCT) data to de-risk studies and improve generalizability. With regulators setting clearer ...

Lou Pillai is the founder of Ulivmo and most recently, he was the Head of Data and Digital at Immunomedics (acquired by Gilead). Ehsan Ehsani is a director of consulting at CGI and leader of ...

Prior to joining Phastar, Billy led the model-based drug development team at Novartis. Then, he developed and led implementation of statistical methodologies for high impact research sponsored by ...

In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size ...